uniQure (NASDAQ:QURE) Lowered to “Hold” Rating by Wells Fargo & Company

uniQure (NASDAQ:QURE) was downgraded by analysts at Wells Fargo & Company from a “strong-buy” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

Several other research analysts have also recently issued reports on QURE. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $9.00 target price (down from $55.00) on shares of uniQure in a report on Monday. Benchmark restated a “buy” rating on shares of uniQure in a report on Tuesday, November 4th. Wall Street Zen downgraded uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Leerink Partners reissued an “outperform” rating and issued a $35.00 target price on shares of uniQure in a report on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a report on Wednesday, January 21st. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $34.33.

uniQure Trading Down 14.0%

uniQure stock opened at $9.03 on Monday. uniQure has a 12 month low of $7.76 and a 12 month high of $71.50. The company has a market capitalization of $562.48 million, a price-to-earnings ratio of -2.62 and a beta of 0.73. The business’s fifty day simple moving average is $22.86 and its two-hundred day simple moving average is $29.72. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.93) by $0.37. The firm had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative return on equity of 230.98% and a negative net margin of 1,236.00%. As a group, equities analysts predict that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Activity at uniQure

In other news, CEO Matthew C. Kapusta sold 12,378 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total transaction of $295,339.08. Following the transaction, the chief executive officer directly owned 639,076 shares of the company’s stock, valued at $15,248,353.36. This represents a 1.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the transaction, the director owned 32,342 shares in the company, valued at approximately $796,260.04. This trade represents a 44.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 50,598 shares of company stock valued at $1,248,588 in the last quarter. 4.79% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On uniQure

A number of large investors have recently made changes to their positions in QURE. Jefferies Financial Group Inc. bought a new position in shares of uniQure in the 2nd quarter worth approximately $29,217,000. State Street Corp increased its holdings in uniQure by 123.8% during the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after buying an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. raised its position in uniQure by 155.3% in the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after acquiring an additional 1,785,275 shares during the period. Avoro Capital Advisors LLC boosted its stake in shares of uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after acquiring an additional 1,705,556 shares during the last quarter. Finally, MPM Bioimpact LLC bought a new stake in shares of uniQure during the 4th quarter valued at $33,062,000. 78.83% of the stock is currently owned by institutional investors.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Q4 results beat the EPS consensus (reported loss narrower than expected) and revenue slightly exceeded estimates — provides near‑term financial relief but did not offset regulatory concerns. Q4 press release
• Positive Sentiment: Some analysts remain constructive after repricing: Chardan retained a “buy” rating (lowered PT) and Wells Fargo kept an “equal weight” stance, which could support buyer interest if worries ease. Analyst notes
• Neutral Sentiment: uniQure says it held a Type A meeting with the FDA, is evaluating Phase‑III plans for AMT‑130 and intends to request a follow‑up Type B meeting in Q2 — this signals a defined regulatory path but will likely take time and resources. Company update
• Neutral Sentiment: Corporate disclosure flagged a governance risk tied to a 2026 shift to the Dutch “large company” regime — a longer‑term structural governance change that bears monitoring but is not an immediate earnings driver. TipRanks note
• Negative Sentiment: Regulatory blow: the FDA told uniQure its early‑stage AMT‑130 data are insufficient for a marketing application and has recommended a randomized, sham‑controlled Phase III study — a materially more onerous and time‑consuming path that triggered the sharp market selloff. Reuters: FDA tells UniQure
• Negative Sentiment: Analysts slashed price targets and ratings after the FDA decision (Goldman lowered its PT to $9 and moved to neutral; Cantor, RBC, Mizuho and others also cut PTs or ratings) — analyst repricing removes supporting buy‑side momentum and amplifies downside risk. Analyst coverage changes
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs for securities class actions tied to the company’s disclosures during a defined class period — increased legal risk, potential settlements or litigation costs add uncertainty for shareholders. Rosen Law Firm notice
• Negative Sentiment: Market reaction: heavy volume and steep price declines since the FDA announcement reflect rapid repricing of AMT‑130’s value and higher execution risk for the company’s lead gene‑therapy program. Bloomberg coverage

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.